MULTIPLE MYELOMA

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas W. Sborov, MD, MS, discussed treatment after a second relapse in a patient with multiple myeloma.

Binod Dhakal, MD, MS, provides background on the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of patients with lenalidomide-refractory multiple myeloma.

In the first article of a 2-part series, Jack Khouri, MD, discussed the challenges that come with the toxicity profile of selinexor and how physicians can manage these adverse events.

In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, highlighted some of the most recent updates in the field of multiple myeloma, and discussed emerging therapies that show promise.

On the heels of positive results from GENESIS, a phase 3 study, the FDA has approved the first stem cell mobilization therapy for multiple myeloma.

Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.

A phase 3 study of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma is discussed by Binod Dhakal, MD, MS.

Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.

Elizabeth "Betsy" O’Donnell, MD, discusses the importance of carrying out different strategies when treating patients with multiple myeloma who are older and frail.

Prerna Mewawalla, MD, discusses how she approaches the choice of therapy for relapsed/refractory multiple myeloma now that many different options are available for patients.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.

In an interview with Targeted Oncology, Binod Dhakal, MD, discussed results from the phase 3 CARTITUDE-4 study of cilta-cel in patients with lenalidomide-refractory multiple myeloma.

In a live, virtual event, Chakra Chaulagain, MD, discussed the results of the GRIFFIN trial in patients with newly diagnosed multiple myeloma when adding daratumumab to their traditional triplet therapy.

In the first article of a 2-part series, Ajay Nooka, MD, MPH, discussed both the initial and follow-up results of the MajesTEC-1 trial that showed the potency of teclistamab in patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, and participants discussed second-line therapy options for a patient with high-risk relapsed multiple myeloma after frontline lenalidomide, bortezomib, and dexamethasone followed by autologous stem cell transplant.

FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.

During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.

Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.

Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.

In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.

George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.